Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Open Access
- 2 December 2022
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (3) , 748-757
Abstract
Aim: To perform a model‐based analysis of the short‐ and long‐term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden. Materials and Methods: The validated Institute for Health Economics Diabetes Cohort Model (IHE‐DCM) was used to estimate health benefits and a 3‐year budget impact, and lifetime costs per quality‐adjusted life years (QALY) gained of increased implementation of adding empagliflozin to standard of care (SoC) for people with type 2 diabetes and eCVD in a Swedish setting. Scenarios with 100%/75%/50% implementation were explored. Analyses were based on 30 model cohorts with type 2 diabetes and eCVD (n = 131 412 at baseline) from national health data registers. Sensitivity analyses explored the robustness of results. Results: Over 3 years, SoC with empagliflozin (100% implementation) versus SoC before empagliflozin resulted in 7700 total life years gained and reductions in cumulative incidence of cardiovascular deaths by 30% and heart failures by 28%. Annual costs increased by 15% from higher treatment costs and increased survival. Half of these benefits and costs are not yet reached with current implementation below 50%. SoC with empagliflozin yielded 0.37 QALYs per person, with an incremental cost‐effectiveness ratio of 16 000 EUR per QALY versus SoC before empagliflozin. Conclusions: Model simulations using real‐world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even from a short‐term perspective.Keywords
Funding Information
- Boehringer Ingelheim (Grant)
This publication has 39 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk EquationsPLOS ONE, 2014
- Review of Utility Values for Economic Modeling in Type 2 DiabetesValue in Health, 2014
- Changes in Diabetes-Related Complications in the United States, 1990–2010New England Journal of Medicine, 2014
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue in Health, 2014
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82Diabetologia, 2013
- Towards Renewed Health Economic Simulation of Type 2 Diabetes: Risk Equations for First and Second Cardiovascular Events from Swedish Register DataPLOS ONE, 2013
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) StatementPharmacoEconomics, 2013
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Guidelines for Computer Modeling of Diabetes and Its ComplicationsDiabetes Care, 2004